Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
First Claim
1. A sterile ophthalmic formulation, comprising:
- a biocompatible chelating agent at a concentration of at least 0.6% by weight;
an effective permeation-enhancing concentration of a permeation enhancer;
an anti-AGE agent selected from AGE breakers, AGE formation inhibitors, and glycation inhibitors; and
a pharmaceutically acceptable ophthalmic carrier.
4 Assignments
0 Petitions
Accused Products
Abstract
An ophthalmic formulation is provided for the prevention and treatment of adverse ocular conditions, including presbyopia, arcus senilis, age-related macular degeneration, and other conditions associated with aging. The formulation is also useful in the prevention and treatment of other adverse ocular conditions such as those associated with oxidative and/or free radical damage within the eye; these conditions can involve a condition, disease, or disorder of the cornea, retina, lens, sclera, anterior segment, or posterior segment of the eye. In one embodiment, the formulation contains at least 0.6 wt. % of a biocompatible chelating agent, an effective permeation enhancing amount of an ophthalmic permeation enhancer such as methylsulfonylmethane (MSM), an anti-AGE agent, i.e., a compound that serves to reduce the presence of advanced glycation endproducts (AGEs) in the eye, and a pharmaceutically acceptable ophthalmic carrier suited to the particular formulation type (e.g., eye drops or ointments). Preferred components of the formulation are multifunctional and naturally occurring.
131 Citations
92 Claims
-
1. A sterile ophthalmic formulation, comprising:
-
a biocompatible chelating agent at a concentration of at least 0.6% by weight;
an effective permeation-enhancing concentration of a permeation enhancer;
an anti-AGE agent selected from AGE breakers, AGE formation inhibitors, and glycation inhibitors; and
a pharmaceutically acceptable ophthalmic carrier. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 89, 90, 91, 92)
-
-
32. The formulation of claim 32, having a pH in the range of about 6.8 to about 7.8.
-
33. A sterile ophthalmic formulation, comprising:
-
a biocompatible chelating agent at a concentration of at least 0.6% by weight;
an effective permeation-enhancing amount of methylsulfonylmethane; and
a pharmaceutically acceptable ophthalmic carrier. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41, 42)
-
-
43. A sterile ophthalmic formulation, comprising:
-
a biocompatible chelating agent at a concentration of at least 0.6% by weight;
an effective AGE-reducing concentration of L-carnosine; and
a pharmaceutically acceptable ophthalmic carrier. - View Dependent Claims (44, 45, 46, 47, 48, 49)
-
- 85. A sterile ocular insert for administration of a biocompatible chelating agent to the eye, comprising a controlled release implant housing a formulation consisting essentially of the biocompatible chelating agent and a pharmaceutically acceptable carrier.
- 87. A sterile ocular insert for administration of an anti-AGE agent to the eye, comprising a controlled release implant housing a formulation consisting essentially of the anti-AGE agent and a pharmaceutically acceptable carrier.
Specification